Status
Conditions
Treatments
About
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling.
Patients who are willing to provide written informed consent.
Exclusion criteria
89 participants in 1 patient group
Loading...
Central trial contact
Novartis Pharmaceuticals; Novartis Pharmaceuticals
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal